COREG MR Versus TOPROL-XL On Reduction Of Microalbuminuria In Patients With Hypertension And Microalbuminuria
Terminated
GlaxoSmithKline
Phase 3
2005-07-01
This study was designed to determine whether COREG MR is more effective than TOPROL-XL in
reducing microalbuminuria in type 2 diabetic or non-diabetic patients with high blood
pressure and microalbuminuria.
COREG MR Versus TOPROL-XL On The Lipid Profile Of Normolipidemic Or Mildly Dyslipidemic Patients With Hypertension
Completed
GlaxoSmithKline
Phase 3
2006-01-05
This study was designed to determine whether treatment with COREG MR is more effective at
maintaining a better lipid profile than treatment with TOPROL-XL for hypertension.
A Study to Compare the Effects of Coreg CR and Coreg IR on Heart Function in Subjects With Stable Chronic Heart Failure
Completed
CTI Clinical Trial and Consulting Services
Phase 3
2006-03-01
The purpose of this study is to determine if Coreg CR is as effective as Coreg IR in
improving heart function in subjects with stable chronic heart failure.
A Study to Compare the Effects of Coreg CR and Coreg IR on Heart Function in Subjects With Stable Chronic Heart Failure
Completed
GlaxoSmithKline
Phase 3
2006-03-01
The purpose of this study is to determine if Coreg CR is as effective as Coreg IR in
improving heart function in subjects with stable chronic heart failure.
A Study to Compare the Effects of Coreg CR and Coreg IR on Heart Function in Subjects With Stable Chronic Heart Failure
Completed
CTI-1, LLC
Phase 3
2006-03-01
The purpose of this study is to determine if Coreg CR is as effective as Coreg IR in
improving heart function in subjects with stable chronic heart failure.
Efficacy of Coreg CR and Lisinopril on Markers for Cardiovascular Functional and Structural Disease
Completed
GlaxoSmithKline
Phase 1/Phase 2
2007-11-01
This study will examine the individual and combined effects of Coreg CR and lisinopril, on
cardiovascular health as measured by Rasmussen Disease Score (RDS) in a blinded, placebo
controlled comparison over a 9-month study period. Patients to be randomized will have
pre-hypertensive blood pressures that do not require anti-hypertensive therapy and at least
one additional cardiovascular risk factor.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
